We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management.
- Authors
Goodarzi, Mark O.; Petrov, Maxim S.
- Abstract
Post-pancreatitis diabetes mellitus, pancreatic cancer-related diabetes, and cystic fibrosis-related diabetes are often underappreciated. As a result, a substantial proportion of people with these sub-types of diabetes receive antidiabetic medications that may be suboptimal, if not harmful, in the context of their underlying disease of the exocrine pancreas. The present article delineates both classical (biguanides, insulin, sulfonylureas, α-glucosidase inhibitors, thiazolidinediones, and meglitinides) and newer (glucagon-like peptide-1 receptor agonists, amylin analogs, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, D2 receptor agonists, bile acid sequestrants, and dual glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor co-agonists) therapies and provides recommendations for managing people with diabetes of the exocrine pancreas based on the most up-to-date clinical evidence. Also, several emerging directions (lipid-enriched pathways, Y4 receptor agonism, glucagon-like peptide-1 and glucagon receptor co-agonism) are presented with a view to informing the process of new drug discovery and development.
- Subjects
PANCREATIC tumors; INSULIN secretagogues; LIFE expectancy; DIABETES; HYPOGLYCEMIC agents; INCRETINS; ISLANDS of Langerhans; CYSTIC fibrosis; THIAZOLIDINEDIONES; SODIUM-glucose cotransporter 2 inhibitors; GLUCAGON-like peptide-1 agonists
- Publication
Drugs, 2023, Vol 83, Issue 12, p1077
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-023-01913-5